PACE-CME.org was present at the ESC 2018 in Munich, Germany. Find coverage of the latest CV news on PACE-CME.
ESC 2018 Dr. Dorresteijn presents how the lifetime risk model U-prevent can estimate the effect of preventive treatment and explains the value of this model in shared decision-making.
Download the meeting impression of this PACE symposium during ESC 2018, which reviewed PCSK9 inhibition with regard to science, outcomes and guidance.
ESC 2018 Biomarkers play an important role in CV risk prediction. Nina Paynter, PhD, presents the definition of a good biomarker and explains how deep learning can improve CV risk assessment.
ESC 2018 Women are still underrepresented in CV clinical trials. Dr. Jeanine Roeters van Lennep explains why sex-specific analyses are important in research into efficacy and safety of CV medication.
ESC 2018 Nicole Jaspers, MD, presents a model that predicts lifetime risk of CV events in individuals without CVD, including lifetime benefit of therapy, which allows shared-decision making in daily practice.
Prof. Jorge Plutzky explains BET inhibition as a novel therapeutic strategy for controlling pathologic cardiovascular responses.
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.
Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.
ESC 2018 Prof. dr. Pieter Vandervoort, Jean-Paul Vendeville and Gijs Berkelmans discuss how digital health can help us screening for atrial fibrillation in general population by using a smartphone.
This is a summary of the presentation by John Kastelein, in which he discusses targeting PCSK9 in clinical practice, focusing on issues surrounding prescription of PCSK9 monoclonal antibodies.
This is a summary of the presentation by Jennifer Robinson, in which she explains that the greatest benefit of PCSK9 antibodies can be obtained at higher LDL-c levels, as seen in high-risk populations.
This is a summary of the presentation by Brian Ference, in which he shows data suggesting that PCSK9 inhibitors and statins have biologically and therapeutically equivalent effects on the risk of CVD.